Research Study

An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL
Principal Investigator 
Yasser Abou Mourad

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
Leukemia
ClinicalTrials.gov# 
NCT03589326
Status 
Recruiting
Study Start/End 
Apr 16, 2021 to Mar 31, 2024
Locations 
Vancouver General Hospital
Name/Title 
Claudia Piechnik, Research Coordinator
Phone 
604-875-4111 ext.22958
Purpose of Study 

The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.